Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948569 · ClinicalTrials.gov registry record · Phase 1
Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
A Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02948569 is a Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 12 participants.
The verdict
NCT02948569, a Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholic fatty liver disease (NAFLD). Recently, drugs that block fatty acid synthesis have been developed to treat cancer. These drugs are now being considered for the treatment of NAFLD. A research test designed to measure liver fatty acid synthesis involves consumption of a sugary solution and measurement of blood fats over a six-hour period. The present study will test the drug 3-V Bioscience-2640 in healthy subjects with characteristics of the metabolic syndrome before and after 10 days of treatment to determine if 50 mg/d significantly reduces liver fat synthesis and lowers liver fat storage.
Interventions
- DRUG 3-V Bioscience-2640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948569
The ClinicalTrials.gov registry entry for NCT02948569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3-V Bioscience-2640 is the first listed.
NCT02948569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948569 about?
NCT02948569 is a clinical study titled "Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome". Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholic fatty liver disease (NAFLD). Recently, drugs that block fatty acid synthesis have been developed to treat canc...
What is the current status of trial NCT02948569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-02-01. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT02948569?
The interventions under investigation include: 3-V Bioscience-2640 (DRUG).
Who is sponsoring clinical trial NCT02948569?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.